Arthur F. Ryan Elected to Regeneron's Board of Directors.Business Editors/Health/Medical Writers BIOWIRE2K TARRYTOWN, N.Y.--(BUSINESS WIRE)--Jan. 17, 2003 Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) announced today that it has elected Arthur F. Ryan to fill a new seat on its expanded Board of Directors. Mr. Ryan is Chairman, Chief Executive Officer, and President of Prudential Financial, Inc., one of the largest diversified financial The diversified financial services segment includes a range of consumer and commercially-oriented companies offering a wide variety of products and services, including various lending products (such as home equity loans and credit cards), insurance, and securities and investment institutions in the world. "Art brings extraordinarily important strategic and financial leadership skills to our Board," noted P. Roy Vagelos Pindaros Roy Vagelos better known as P. Roy Vagelos or Roy Vagelos (born 1929 in Westfield, New Jersey) was president and chief executive officer (1985) and chairman (1986) of Merck, he was widely admired for attracting top research scientists who developed many major , M.D., Chairman of Regeneron's Board of Directors. "With our broad therapeutic pipeline and emerging opportunities for several product candidates, we'll benefit from Art's significant experience in managing complex businesses. He'll help us plan Regeneron's business growth. We're delighted to have Art join our Board." Mr. Ryan joined Prudential in December 1994, and he led the company's strategic conversion from a mutual to a publicly traded company publicly traded company A company whose shares of common stock are held by the public and are available for purchase by investors. The shares of publicly traded firms are bought and sold on the organized exchanges or in the over-the-counter market. in 2001. Prior to joining Prudential in December 1994, he had been President and Chief Operating Officer Chief Operating Officer (COO) The officer of a firm responsible for day-to-day management, usually the president or an executive vice-president. of Chase Manhattan Bank The Chase Manhattan Bank, now part of JPMorgan Chase, was formed by the merger of the Chase National Bank and the Bank of the Manhattan Company in 1955. The bank is headquartered in New York City. since 1990. Mr. Ryan ran Chase's worldwide retail bank between 1984 and 1990. Regeneron is a biopharmaceutical company that discovers, develops, and intends to commercialize therapeutic medicines for the treatment of serious medical conditions See carpal tunnel syndrome, computer vision syndrome, dry eyes and deep vein thrombosis. . Regeneron has therapeutic candidates for the potential treatment of obesity, rheumatoid arthritis rheumatoid arthritis Chronic, progressive autoimmune disease causing connective-tissue inflammation, mostly in synovial joints. It can occur at any age, is more common in women, and has an unpredictable course. , cancer, and asthma and has preclinical programs in other diseases and disorders. This news release discusses historical information and includes forward-looking statements about Regeneron and its products, programs, finances, and business, all of which involve a number of risks and uncertainties, such as risks associated with preclinical and clinical development of drugs and biologics, determinations by regulatory and administrative governmental authorities, competitive factors, technological developments, the availability and cost of capital, the costs of developing, producing, and selling products, the potential for any collaboration agreement to be canceled or to terminate without any product success, and other material risks. A more complete description of these risks can be found in Regeneron's filings with the United States Securities and Exchange Commission, including its Form 10-K Form 10-K A report required by the SEC from exchange-listed companies that provides for annual disclosure of certain financial information. Form 10-K See 10-K. for the year ended December 31, 2001 and the Form 10-Q Form 10-Q See 10-Q. for the quarter ended September 30, 2002. Regeneron does not undertake any obligation to update publicly any forward-looking statement, whether as a result of new information, future events, or otherwise, unless required by law. Additional information about Regeneron and recent news releases are available on Regeneron's Worldwide Web Home Page at www.regn.com. Fax copies of news releases can be obtained from Regeneron's News-on-Demand Service by dialing 800.311.0841. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion